Austedo XR TD is a medication used to treat tardive dyskinesia (TD) and chorea associated with Huntington's disease [1]. It is an extended-release formulation of deutetrabenazine [1][2].
What is Tardive Dyskinesia (TD)?
Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive body movements, often affecting the face, tongue, lips, or jaw, but can also involve the limbs and trunk [1][3]. These movements can be rapid and jerky or slow and writhing [3]. TD is often a side effect of long-term use of certain medications, particularly antipsychotics [3].
How does Austedo XR TD work?
Austedo XR TD contains deutetrabenzine, which is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT2) [2]. VMAT2 is a protein in the brain that helps regulate the amount of dopamine available for release [2]. By inhibiting VMAT2, deutetrabenzine reduces the amount of dopamine in the brain, which can help control the involuntary movements associated with TD and Huntington's disease [2].
What is the difference between Austedo and Austedo XR?
Austedo is the immediate-release formulation of deutetrabenzine, while Austedo XR is the extended-release formulation [1][2]. The XR (extended-release) formulation is designed to release the medication slowly over time, allowing for less frequent dosing compared to the immediate-release version [1]. This can improve convenience and potentially adherence for patients [1].
When does the patent for Austedo XR expire?
Patent information for specific drugs like Austedo XR can be complex and is subject to change due to patent extensions, litigation, and new patent filings. For detailed and up-to-date information on Austedo XR's patent status, including potential expiry dates and any ongoing legal challenges, it is recommended to consult resources like DrugPatentWatch.com [4].
What are the side effects of Austedo XR TD?
Common side effects associated with Austedo XR TD include sleepiness, fatigue, dry mouth, constipation, and nausea [1]. It is important to discuss any potential side effects with a healthcare provider [1].
Who makes Austedo XR TD?
Austedo XR TD is manufactured by Teva Pharmaceuticals [1].
What clinical data supports Austedo XR TD's efficacy?
Clinical trials have demonstrated the efficacy of deutetrabenzine in reducing the severity of tardive dyskinesia movements [2]. Studies have shown statistically significant improvements in the Abnormal Involuntary Movement Scale (AIMs) scores for patients treated with deutetrabenzine compared to placebo [2].
What are the risks associated with Austedo XR TD?
A significant risk associated with Austedo XR TD is the potential for depression and suicidal ideation or behavior [1]. Patients should be monitored for these symptoms, especially those with a history of depression [1]. Other risks can include parkinsonism, somnolence, and QTc prolongation [1].
Are there alternatives to Austedo XR TD for tardive dyskinesia?
Other medications approved for the treatment of tardive dyskinesia include valbenazine (Ingrezza) and tetrabenazine (Xenazine) [5]. The choice of treatment depends on individual patient factors, including medical history, other medications, and physician preference [5].
How is Austedo XR TD dosed?
Austedo XR TD is taken once daily [1]. The starting dose and titration schedule are determined by the prescribing physician based on individual patient needs and response [1].
What insurance coverage is available for Austedo XR TD?
Insurance coverage for Austedo XR TD can vary by plan and provider. Patients are advised to check with their insurance provider or refer to manufacturer resources for information on coverage and potential patient assistance programs [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/austedo-xr
[2] https://www.drugpatentwatch.com/drugs/austedo
[3] https://www.ninds.nih.gov/health-information/disorders/tardive-dyskinesia
[4] https://www.drugpatentwatch.com/
[5] https://www.nejm.org/doi/full/10.1056/NEJMcp2306923